TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology Positive Results from First Patient Treated with TFF VORI Recently Presented at the 15th Annual International Congress on Lung Transplantation

Daniel Carlson

November 1, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

5 COMMENTS

Peter F November 1, 2022 at 7:40 pm

You need to login to view this content.

Reply
- Daniel Carlson November 1, 2022 at 8:01 pm
  
  You need to login to view this content.
  
  Reply
  - pfalker November 1, 2022 at 8:39 pm
    
    You need to login to view this content.
    
    Reply
    - Daniel Carlson November 1, 2022 at 8:44 pm
      
      You need to login to view this content.
      
      Reply
wpeter41 November 1, 2022 at 4:50 pm

You need to login to view this content.

Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.